Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Filings indexed 456 across all filing types
Latest filing 2026-05-01 Annual Report
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
20-F - Tiziana Life Sciences Ltd (0001723069) (Filer)
Annual Report
2026-05-01 English
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
Foreign Filer Report
2026-04-16 English
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
Foreign Filer Report
2026-04-14 English
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
Foreign Filer Report
2026-04-01 English
3 - Tiziana Life Sciences Ltd (0001723069) (Issuer)
Director's Dealing
2026-03-19 English
6-K Filing
Foreign Filer Report
2026-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.